On 8th November 2012, the Federal Drugs Administration in the United States received guidance from its Endocrinologic and Metabolic Drugs Advisory Committee on the application for a license for degludec insulin and its combination preparation degludec/aspart. Although the committee had voted in favour of a license there was a recommendation for a study of cardiovascular (CV) safety. This is in marked contrast to the opinion of the European Medicines Agency and Japanese authorities who were satisfied with the CV analyses. So, why should there be this divergence of opinion and who has got it right?
The Alliance continues to reinforce its commitment to diabetes with data presentations on three molecules in three product classes, across type 1 and type 2 diabetes (Lilly)
App serves as a teaching tool and can provide guidance for treatment with Lilly Glucagon for Injection (rDNA origin) during severe hypoglycemic events (Lilly)
Diabetology Limited and USV Limited, a Leading Indian Pharmaceutical Company, Announce an Exclusive Licence Agreement to Develop and Commercialise Oral Insulin for the Indian Market (Diabetology)
To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease (World Pharma News)